DGAP-News

DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE DIRECTOR OF PAION INC - Seite 2

Medicine. Dr. Bernstein has authored over 100 publications, 10 book
chapters, and has been the principle investigator in more than 100 clinical
trials. His work has been published in such prestigious journals as the New
England Journal of Medicine and The Lancet.

Dr. Bernstein has held elective offices in many national and international
societies. He is the current president of the Bockus International Society
of Gastroenterology and a former president of the New York Gastrointestinal
Association. He served for six years as the American College of
Gastroenterology governor for Long Island and was a member of numerous
other medical committees. Currently, he is a fellow of the American
Association for the Study of Liver Diseases, the American College of
Gastroenterology and the American College of Physicians. He also serves as
a special consultant to the New York State Department of Health. He has
received numerous awards recognizing his contributions, in academia, as a
clinician, and in the field of public health.

"I am delighted to be involved with Remimazolam, a welcome alternative for
which gastroenterologists have waited many years. I look forward to the
challenges ahead and I am confident that we will see the potential of
Remimazolam fully realized in the United States," commented Dr. Bernstein.

PAION will be present at the Digestive Disease week (DDW 2015) between May
17-19, 2015 in Washington, U.S. and will be available for discussions at
booth 1865 in the exhibition hall.

About Remimazolam
Remimazolam is an innovative ultra-short-acting general
sedative/anesthetic. As a result of its short duration of action and good
controllability, it has a preferable efficacy and safety profile relative
to other currently marketed anesthesia compounds. Remimazolam's rapid
offset is a consequence of its metabolism by tissue esterase enzymes that
are widely distributed throughout the body. Remimazolam has potential in
three indications:

- Procedural sedation (Lead indication U.S.)

- General anesthesia (Lead indication EU, Japan)

- ICU sedation (Phase II Japan)

Remimazolam is available for licensing outside China, Russia (CIS) Turkey,
MENA Region, South Korea and Canada, where the compound is partnered with
Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm.

About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The